Future strategies in microbicide development

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 26, Issue 4, 2012, Pages 503-513

  Rosenberg, Zeda F ^a   Devlin, Brid ^a  

^a INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

Author keywords

contraceptive; HIV infection; microbicides; sexually transmitted infections; vaginal rings

Indexed keywords

ACICLOVIR; CARRAGEENAN; DAPIVIRINE; DARUNAVIR; DS 003; ELVITEGRAVIR; ESTRADIOL; ESTRADIOL ACETATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETONOGESTREL; LEVONORGESTREL; MARAVIROC; MICROBICIDE; MIV 150; NORETHISTERONE ACETATE; PLACEBO; RALTEGRAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZINC ACETATE;

DRUG DOSAGE FORM; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; EMERGENCY CONTRACEPTION; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREGNANCY; PRIORITY JOURNAL; PROSTITUTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUPPOSITORY; VAGINA RING; VAGINAL ULCER; VAGINITIS; VIRUS LOAD; VIRUS REPLICATION;

EID: 84862857106     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2012.02.001     Document Type: Article

References (77)

1. Karim QA, Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-1174.
2. Woolfson AD, Malcolm RK & Gallagher R. Drug delivery by the intravaginal route. Crit Rev Ther Drug Carrier Syst 2000; 17: 509-555.
3. Friend DR. Pharmaceutical development of microbicide drug products. Pharm Dev Technol 2010; 15: 562-581.
4. Nel AM, Mitchnick LB, Risha P et al. Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women. J Womens Health (Larchmt) 2011; 20: 1207-1214.
5. D'Cruz OJ & Uckun FM. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 2006; 57: 411-423. (Pubitemid 43240192)
6. Jespers VA, Van Roey JM, Beets GI et al. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immune Defic Syndr 2007; 44: 154-158. (Pubitemid 46292217)
7. Van Herrewege Y, Michiels J, Van Roey J et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004; 48: 337-339. (Pubitemid 38040219)
8. Njai HF, Lewi PJ, Janssen CG et al. Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells. Antivir Ther 2005; 10: 255-262. (Pubitemid 41151032)
9. Fletcher P, Harman S, Azijn H et al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2009; 53: 487-495.
10. Das K, Clark ADJ, Lewi PJ et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47: 2550-2560. (Pubitemid 38580092)
11. Di Fabio S, Van Roey J, Giannini G et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 gel formulation. AIDS 2003; 17: 1597-1604. (Pubitemid 36951680)
12. Garg S, Kandarapu R, Vermani K et al. Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges. AIDS Patient Care STDS 2003; 17: 17-32. (Pubitemid 36083819)
13. Dhondt MM, Adriaens E, Roey JV et al. The evaluation of the local tolerance of vaginal formulations containing dapivirine using the Slug Mucosal Irritation test and the rabbit vaginal irritation test. Eur J Pharm Biopharm 2005; 60: 419-425. (Pubitemid 40922840)
14. Nuttall JP, Thake DC, Lewis MG et al. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days. Antimicrob Agents Chemother 2008; 52: 909-914. (Pubitemid 351358369)
15. Nel AM, Coplan P, Smythe SC et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 2010; 26: 1181-1190.
16. *Nel AM, Smythe SC, Habibi S et al. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 2010; 55: 161-169.
17. Nel AM, Coplan P, van de Wijgert JH et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 2009; 23: 1531-1538.
18. Romano J, Malcolm RK, Garg S et al. Microbicide delivery: formulation technologies and strategies. Curr Opin HIV AIDS 2008; 3: 558-566.
19. Bounds W, Szarewski A, Lowe D et al. Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring. Eur J Obstet Gynecol Reprod Biol 1993; 48: 123-125. (Pubitemid 23108943)
20. Roumen F, Dieben T, Assendorp R et al. The clinical acceptability of a non-medicated vaginal ring. Contraception 1990; 42: 201-217.
21. Weisberg E, Fraser IS, Baker J et al. A randomized comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of a ring. Contraception 2000; 62: 83-89.
22. Roumen FJ & Dieben TO. Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring. Contraception 1999; 59: 59-62. (Pubitemid 29174417)
23. Fraser IS, Lacarra M, Mishell DR et al. Vaginal epithelial surface appearances in women using vaginal rings for contraception. Contraception 2000; 61: 131-138. (Pubitemid 30236334)
24. Malcolm RK, Woolfson AD, Toner CF et al. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 2005; 56: 954-956. (Pubitemid 41631926)
25. Woolfson AD, Malcolm RK, Morrow RJ et al. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 2006; 325: 82-89. (Pubitemid 44573697)
26. Bell SE, Dennis AC, Fido LA et al. Characterization of silicone elastomer vaginal rings containing HIV microbicide TMC120 by Raman spectroscopy. J Pharm Pharmacol 2007; 59: 203-207. (Pubitemid 46203059)
27. Romano J, Variano B, Coplan P et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009; 25: 483-488.
28. Gupta KM, Pearce SM, Poursaid AE et al. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci 2008.
29. Nel A, Smythe S, Young K et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009; 51: 416-423.
30. Garg AB, Nuttall J & Romano J. The future of HIV microbicides: challenges and opportunities. Antivir Chem Chemother 2009; 19: 143-150.
31. Nuttall J. Microbicides in the prevention of HIV infection: current status and future directions. Drugs 2010; 70: 1231-1243.
32. Dieben TO, Roumen FJ & Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002; 100: 585-593. (Pubitemid 35246150)
33. Faundes A, Hardy E, Reyes C et al. Acceptability of the contraceptive vaginal ring by rural and urban population in two Latin American countries. Contraception 1981; 24: 393-414. (Pubitemid 12239510)
34. Weisberg E, Fraser IS, Mishell Jr. DR et al. The acceptability of a combined oestrogen/progestogen contraceptive vaginal ring. Contraception 1995; 51: 39-44.
35. Novak A, de la Loge C, Abetz L et al. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 2003; 67: 187-194. (Pubitemid 36255655)
36. Lete I, Doval JL, Perez-Campos E et al. Factors affecting women's selection of a combined hormonal contraceptive method: the TEAM-06 Spanish cross-sectional study. Contraception 2007; 76: 77-83. (Pubitemid 47090168)
37. Roumen FJ. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 2007; 75: 420-429. (Pubitemid 46764299)
38. Creinin MD, Meyn LA, Borgatta L et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol 2008; 111: 267-277. (Pubitemid 351653415)
39. Lete I, Doval JL, Perez-Campos E et al. Self-described impact of noncompliance among users of a combined hormonal contraceptive method. Contraception 2008; 77: 276-282.
40. Smith DJ, Wakasiaka S, Hoang TD et al. An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: behaviors and attitudes that might influence uptake within a high-risk population. J Womens Health (Larchmt) 2008; 17: 1025-1034.
41. *Akil A, Parniak M, Dezzutti C et al. Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv and Transl Res 2011; 1: 209-222.
42. Raymond E, Alvarado G, Ledesma L et al. Acceptability of two spermicides in five countries. Contraception 1999; 60: 45-50. (Pubitemid 29505355)
43. Raymond EG, Chen PL, Condon S et al. Acceptability of five nonoxynol-9 spermicides. Contraception 2005; 71: 438-442. (Pubitemid 40725780)
44. Steiner M, Spruyt A, Joanis C et al. Acceptability of Spermicidal Film and Foaming Tablets Among Women in Three Countries. Int Fam Plan Perspect 1995; 21: 104-107.
45. Visness CM, Ulin P, Pfannenschmidt S et al. Views of Cameroonian sex workers on a woman-controlled method of contraception and disease protection. Int J STD AIDS 1998; 9: 695-699. (Pubitemid 28537780)
46. Rustomjee R, Abdool Karim Q, Abdool Karim SS et al. Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. AIDS 1999; 13: 1511-1515. (Pubitemid 29396683)
47. Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-4732. (Pubitemid 41552605)
48. MacArthur RD & Novak RM. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008; 47: 236-241. (Pubitemid 351920626)
49. *Hu Q, Frank I, Williams V et al. Blockade of Attachment and Fusion Receptors Inhibits HIV-1 Infection of Human Cervical Tissue. J Exp Med 2004; 199: 1065-1075. (Pubitemid 38619903)
50. Veazey RS, Ketas TJ, Dufour J et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 2010; 202: 739-744.
51. Antoniou T, Park-Wyllie LY & Tseng AL. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy 2003; 23: 29-43. (Pubitemid 36077364)
52. Thurman AR, Clark MR & Doncel GF. Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol 2011; 2011: 1-10.
53. Fernandez-Romero JA, Thorn M, Turville SG et al. Carrageenan/MIV-150 (PC-815), a Combination Microbicide. Sex Transm Dis 2007; 34: 9-14. (Pubitemid 46041501)
54. Turville SG, Aravantinou M, Miller T et al. Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 2008; 3: e3162.
55. *Kenney J, Aravantinou M, Singer R et al. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 2011; 6: e15835.
56. Lin PF, Blair W, Wang T et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A 2003; 100: 11013-11018. (Pubitemid 37140144)
57. Guo Q, Ho HT, Dicker I et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol 2003; 77: 10528-10536. (Pubitemid 37129696)
58. Si Z, Madani N, Cox JM et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A 2004; 101: 5036-5041. (Pubitemid 38469198)
59. Kadow J, Wang HG & Lin PF. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development. Curr Opin Investig Drugs 2006; 7: 721-726. (Pubitemid 44263176)
60. *Veazey RS, Klasse PJ, Schader SM et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438: 99-102. (Pubitemid 41599827)
61. Terrazas-Aranda K, Van Herrewege Y, Hazuda D et al. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob Agents Chemother 2008; 52: 2544-2554. (Pubitemid 351915687)
62. Wilkin TJ, Taylor B, Olender S et al. Advances in antiretroviral therapy. Top HIV Med 2008; 16: 31-60.
63. Zolopa AR, Berger DS, Lampiris H et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010; 201: 814-822.
64. Haase AT. Early Events in Sexual Transmission of HIV and SIV and Opportunities for Interventions. Annu Rev Med 2011; 62: 127-139.
65. Sobieszczyk ME, Talley AK, Wilkin T et al. Advances in antiretroviral therapy. Top HIV Med 2005; 13: 24-44.
66. Martinez J, Coplan P & Wainberg MA. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? Antiviral Res 2006; 71: 343-350. (Pubitemid 44223773)
67. Johnson TJ, Srinivasan P, Albright TH et al. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 2011 [e-pub ahead of print].
68. Visseaux B, Charpentier C, Hurtado-Nedelec M et al. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors. Antimicrob Agents Chemother 2012; 56: 137-139.
69. Rieder P, Joos B, Scherrer AU et al. Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clin Infect Dis 2011; 53: 1271-1279.
70. Johnson TJ, Gupta KM, Fabian J et al. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci 2010; 39: 203-212.
71. Schader SM, Colby-Germinario SP, Schachter JR et al. Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination. AIDS 2011; 25: 1585-1594.
72. Corey L, Wald A, Patel R et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350: 11-20. (Pubitemid 38032179)
73. Glasier A, Gulmezoglu AM, Schmid GP et al. Sexual and reproductive health: a matter of life and death. Lancet 2006; 368: 1595-1607. (Pubitemid 44691893)
74. Koetsawang S, Ji G, Krishna U et al. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects.World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 1990; 41: 105-124.
75. Mertenskoetter T & Kaptur PE. Update on microbicide research and development - seeking new HIV prevention tools for women. Eur J Med Res 2011; 16: 1-6.
76. Schwartz JL, Ballagh SA, Creinin MD et al. SILCS diaphragm: postcoital testing of a new single-size contraceptive device. Contraception 2008; 78: 237-244.
77. Andrei G, Lisco A, Vanpouille C et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 2011; 10: 379-389.